SCHEMBL21035392

SCHEMBL21035392

COC(=O)[C@@H]1C[C@H](Oc2ccc(C(F)(F)F)cc2)CCN1S(=O)(=O)c1ccc(OCC2CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.45
HCRTR2 O43614 3/20 0.45
KCNQ1 P51787 1/20 0.44
MMP1 P03956 5/20 0.43
ADAM17 P78536 5/20 0.43
MMP13 P45452 3/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
KMT2A Q03164 1/20 0.41
BRD4 O60885 2/20 0.40
MMP2 P08253 2/20 0.40
MAPT P10636 1/20 0.40
BRD2 P25440 1/20 0.40
EPHX2 P34913 1/20 0.39
ACACB O00763 1/20 0.39
ENPP3 O14638 1/20 0.39
ENPP2 Q13822 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21035539 1.00 HCRTR1 (0.45) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035415 1.00 HCRTR1 (0.45) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035394 0.91 ADAM17 (0.42) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035414 0.91 ADAM17 (0.42) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035537 0.91 ADAM17 (0.42) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035339 0.89 MMP1 (0.47) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035335 0.89 MMP1 (0.47) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035336 0.89 MMP1 (0.47) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035575 0.87 MMP1 (0.46) HCRTR1HCRTR2KCNQ1MMP1ADAM17
SCHEMBL21035083 0.87 MMP1 (0.46) HCRTR1HCRTR2KCNQ1MMP1ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed